Medexus Generates Record Revenue of US$113.1 Million in Fiscal Year 2024
Ontario and Chicago, Illinois--(Newsfile Corp. - June 25, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company's fourth fiscal quarter and fiscal year ended March 31, 2024 (the company's fiscal Q4 2024 and fiscal year 2024). All dollar amounts in this press release are in United States dollars unless specified otherwise. Financial highlights Record revenue of $113.1 million for fiscal year...
2024-06-25 5:36 PM EDT
Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2024 Conference Call
Ontario and Chicago, Illinois--(Newsfile Corp. - June 18, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Wednesday, June 26, 2024 to discuss Medexus's results for its fourth fiscal quarter and fiscal year ended March 31, 2024. Medexus expects to file its financial statements and MD&A after markets close on June 25, 2024. To participate in the call, please dial the following numbers: 888-506-0062 (toll-free) for Canadian and...
2024-06-18 5:00 PM EDT
FDA Accepts for Review Treosulfan NDA Resubmission
Ontario and Chicago, Illinois--(Newsfile Corp. - June 6, 2024) - On Thursday, June 6, 2024, Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) was informed by medac, licensor of Medexus's commercialization rights to treosulfan, that the US Food and Drug Administration has accepted for review medac's April 2024 resubmission of the New Drug Application for treosulfan. Medexus expects that the FDA will complete its review of the treosulfan NDA and issue a decision by October 30, 2024. The...
2024-06-06 10:18 AM EDT
Medexus Concludes Metoject Litigation, Patent No Longer in Effect in Canada
Ontario and Chicago, Illinois--(Newsfile Corp. - May 1, 2024) - Following a trial in January 2023, Canada's Federal Court has issued a judgment declining to uphold the Canadian patent for Metoject®. Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) and medac, licensor of Medexus's commercialization rights to Metoject®, have elected not to appeal the trial court decision. Medexus and medac initiated the litigation in August 2020 in response to the "at-risk" launch of a generic version of...
2024-05-01 5:30 PM EDT
Medexus to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference
Ontario and Chicago, Illinois--(Newsfile Corp. - April 2, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that company management will be participating in the 2024 Bloom Burton & Co. Healthcare Investor Conference from April 16 to 17, 2024. Event: 2024 Bloom Burton & Co. Healthcare Investor Conference Date: April 16-17, 2024 Location: Toronto, Ontario Medexus Presentation: Wednesday, April 17 at 1:30 PM Eastern time Ken d'Entremont, Medexus's Chief Executive...
2024-04-02 7:30 AM EDT
FDA Approves Medexus's Supplemental Biologics License Application for IXINITY(R) to Treat Hemophilia B in Pediatric Patients
Ontario and Chicago, Illinois--(Newsfile Corp. - March 26, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced that the US Food and Drug Administration (FDA) recently approved Medexus's supplemental Biologics License Application (sBLA) for IXINITY® [coagulation factor IX (recombinant)] for the on-demand, prophylactic, and perioperative treatment of pediatric patients under 12 years of age with hemophilia B. IXINITY®, an intravenous recombinant factor IX therapeutic, is...
2024-03-26 7:53 AM EDT
Medexus Announces Fiscal Q3 2024 Results
Ontario and Chicago, Illinois--(Newsfile Corp. - February 7, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company's third fiscal quarter ended December 31, 2023 (the company's fiscal Q3 2024). All dollar amounts in this news release are in United States dollars unless specified otherwise. Financial highlights Revenue of $25.2 million and $87
2024-02-07 5:58 PM EST
Medexus Schedules Third Fiscal Quarter 2024 Conference Call
Ontario and Chicago, Illinois--(Newsfile Corp. - January 30, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, February 8, 2024 to discuss Medexus's results for its third fiscal quarter ended December 31, 2023. Medexus expects to file its financial statements and MD&A after markets close on February 7, 2024. To participate in the call, please dial the following numbers: 888-506-0062 (toll-free) for Canadian and U.S....
2024-01-30 7:00 AM EST
Health Canada Accepts for Review Medexus's New Drug Submission for Topical Terbinafine
Ontario and Chicago, Illinois--(Newsfile Corp. - January 8, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced that Health Canada recently accepted for review Medexus's new drug submission, or NDS, for terbinafine hydrochloride nail lacquer to treat fungal nail infections. "Health Canada's commitment to review our NDS brings us a step closer to making topical terbinafine a viable treatment option for Canadians," said Richard Labelle, Medexus's General
2024-01-08 7:00 AM EST
Medexus Announces Strong Fiscal Q2 2024 Results, Including Quarterly Revenue of US$30.3 Million
Ontario and Chicago, Illinois--(Newsfile Corp. - November 8, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company's second fiscal quarter ended September 30, 2023 (the company's fiscal Q2 2024). All dollar amounts in this news release are in United States dollars unless specified otherwise. Financial highlights Rev
2023-11-08 5:30 PM EST
Medexus Schedules Second Fiscal Quarter 2024 Conference Call
Ontario and Chicago, Illinois--(Newsfile Corp. - November 1, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, November 9, 2023 to discuss Medexus's results for its second fiscal quarter ended September 30, 2023. Medexus expects to file its financial statements and MD&A after markets close on November 8, 2023. To participate in the call, please dial the following numbers: 888-506-0062 (toll-free) for Canadian and...
2023-11-01 7:00 AM EDT
Medexus Announces Full Exercise and Closing of Over-Allotment Option in Bought-Deal Public Offering
Ontario and Chicago, Illinois--(Newsfile Corp. - October 17, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that, in connection with its recently completed bought-deal public offering (Offering) of units (Units), Medexus has issued an additional 508,484 Units at a price of C$2.95 per Unit for an additional C$1.5 million in gross proceeds following exercise in full by Research Capital Corporation (Underwriter) of the Underwriter's over-allotment option...
2023-10-17 9:15 AM EDT
Medexus Fully Repays Convertible Debentures In Cash At Maturity
Ontario and Chicago, Illinois--(Newsfile Corp. - October 16, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) has made in cash the final maturity date payment of C$51.1 million (or approximately US$37.5 million) to Computershare Trust Company of Canada as trustee for holders of Medexus's 6% unsecured convertible debentures due October 16, 2023 (TSX: MDP.DB). Under the terms of the indenture governing the convertible debentures, each holder will be entitled to receive from the trustee...
2023-10-16 7:00 AM EDT
Medexus Announces Closing of C$10 Million Bought-Deal Public Offering
Ontario and Chicago, Illinois--(Newsfile Corp. - October 6, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce the closing of its bought-deal public offering of 3,389,900 units (Units) at a price of C$2.95 per Unit for aggregate gross proceeds to Medexus of C$10,000,205 (Offering). The net proceeds from the Offering, after deducting underwriting discounts and commissions and offering expenses, will be used for working capital and general corporate purposes, which...
2023-10-06 9:43 AM EDT
Medexus and medac Agree to Amend US Treosulfan Agreement
Ontario and Chicago, Illinois--(Newsfile Corp. - September 28, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that the company recently entered into a third amendment to its February 2021 exclusive license agreement with medac GmbH relating to commercialization of treosulfan in the United States. Among other things, the third amendment extends the agreed outside date for FDA approval to reflect the current status of the FDA regulatory review process, and...
2023-09-28 7:34 PM EDT
Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors
Ontario and Chicago, Illinois--(Newsfile Corp. - September 21, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today held its virtual annual meeting of shareholders. Medexus shareholders elected all nominees listed in Medexus's management information circular dated August 9, 2023 as directors through the next annual meeting. Shareholders also voted in favor of the appointment of PricewaterhouseCoopers LLP as the company's auditors and in favor of resolutions amending the company's...
2023-09-21 5:00 PM EDT
Medexus Strengthens Balance Sheet with US$18 Million Commitment Under Accordion Facility
Ontario and Chicago, Illinois--(Newsfile Corp. - September 5, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today entered into an amendment to the company's senior secured credit agreement with BMO as agent and lender. The amendment provides for a US$18 million increase in BMO's term loan commitment under the existing facility's previously disclosed accordion feature, among other amendments. Medexus intends to apply the full US$18 million, net of any transaction expenses, toward...
2023-09-05 7:30 AM EDT
Medexus Study Supports Efficacy and Safety of IXINITY in Pediatric Patients with Severe or Moderately Severe Hemophilia B
Ontario and Chicago, Illinois--(Newsfile Corp. - August 17, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced the presentation of data from a Phase 3/4 study that evaluated the pharmacokinetics (PK), safety, and efficacy of IXINITY, an intravenous recombinant factor IX therapeutic, as a prophylactic treatment in previously treated pediatric pati
2023-08-17 5:30 PM EDT
Medexus Announces Strong Fiscal Q1 2024 Results, Including Record Quarterly Revenue of US$31.6 Million
Ontario and Chicago, Illinois--(Newsfile Corp. - August 9, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company's first fiscal quarter ended June 30, 2023 (the company's fiscal Q1 2024). All dollar amounts in this news release are in United States dollars unless specified otherwise. Financial highlights Record total
2023-08-09 5:30 PM EDT
Medexus to Participate in Fireside Chat at SHARE Series Event
Ontario and Chicago, Illinois--(Newsfile Corp. - August 4, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that company management will present at the SHARE Series event on Monday, August 14, 2023 at 8:30 AM Eastern time. Event: SHARE Series Date: August 14, 2023 Location: Virtual Presentation Medexus Presentation: Monday, August 14 at 8:30 AM Eastern time Ken d'Entremont, Medexus's Chief Executive Officer, and Marcel Konrad, Medexus's Chief Financial Officer,...
2023-08-04 7:00 AM EDT